We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Panitumumab-Induced Interstitial Lung Disease in a Case of Metastatic Colorectal Cancer.
- Authors
Yamada, Takeshi; Moriwaki, Toshikazu; Matsuda, Kenji; Yamamoto, Yoshiyuki; Sugaya, Akinori; Akutsu, Daisuke; Murashita, Tetsuya; Endo, Shinji; Hyodo, Ichinosuke
- Abstract
Background: A Japanese postmarketing survey of panitumumab revealed that panitumumab-associated interstitial lung disease (ILD) occurred in approximately 1% (19/1767) of patients, causing death in 36.8% of these cases. Case Report: We report the case of a 60-year-old Japanese man who developed ILD associated with panitumumab therapy (third-line therapy) for metastatic sigmoid colon cancer involving the liver, lymph nodes, and lungs. 2 months after the initiation of panitumumab therapy, he developed a progressive nonproductive cough, dyspnea, and a fever, and was diagnosed with ILD. Intravenous pulse methylprednisolone treatment led to quick recovery. The patient had some risk factors for ILD associated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. Conclusion: Further studies are required to elucidate the association between anti-EGFR antibodies and ILD.
- Publication
Oncology Research & Treatment, 2013, Vol 36, Issue 4, p209
- ISSN
2296-5270
- Publication type
Article
- DOI
10.1159/000349959